louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06066463: My Skin & Hair Journey_virtual Registry
Official title: My Skin & Hair Journey_virtual Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Skin
Hair
Lead sponsor: L'Oreal
Sponsor class: INDUSTRY
Collaborators: name: Verily Life Sciences
First posted: 2023-10-04
Enrollment: 10000
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy Female self declared

Brief summary: This is a longitudinal, observational, direct to participant registry to better understand biological, clinical, and environmental aspects of skin/hair health and beauty.

Detailed description: This is a longitudinal, observational, direct to participant registry to better understand biological, clinical, and environmental aspects of skin/hair health and beauty. By collecting, organizing, and analyzing data for a group of participants over time, researchers will use information to learn more about these topics. This study will collect long-term information about study participants, developing a lean, participant-centric approach to curating meaningful longitudinal data that incorporate participant perspectives including quality of life and personal beauty health preferences. This should allow researchers to understand how participant skin health changes over time and what factors can inﬂuence those changes with a speciﬁc focus on participant-centric learning.

Additionally, this study will look for ways to develop and/or improve data handling approaches to increase the depth, generalizability, and/or longitudinality of skin health and beauty data based on approaches that decrease burden, as appropriate, over time (eg, for study participants, investigators, clinical research stakeholders)

Eligibility criteria: Inclusion Criteria:

* Willing and able to provide informed consent
* Willing and able to provide applicable privacy authorization(s)
* Current resident of the United States
* 18 to 70 years of age at the time of informed consent Self identiﬁed female gender
* Able to read and understand English and/or Spanish
* Ability to access internet based study-related tools (eg, applications, software, email notiﬁcations)
* Willingness to use study web/mobile applications (eg, selﬁe assistant, air quality and weather monitoring)

Exclusion Criteria:

- Employee of the Sponsor(s), contracted research organizations, or virtual research sites

Primary outcomes:
measure: Collect and organize a longitudinal skin & hair beauty registry
timeFrame: 18 months
Secondary outcomes:
measure: Build and improve generalizable beauty knowledge
timeFrame: 18 months
measure: improve insights from longitudinal data
timeFrame: 18 months
Other outcomes:
Locations:
city: South San Francisco
country: United States
facility: Verily Life Sciences
state: California
Study officials:
affiliation: Verily Life Sciences
name: KRISDA CHAIYACHATI, MD MPH FACP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05701163: Assessing the Effect of Abstinence Period on Semen Parameters
Official title: Assessing the Effect of Abstinence Period on Semen Parameters
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Infertility, Male
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
First posted: 2023-01-27
Enrollment: 0
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The goal of this study is to learn about the impact of abstinence periods on sperm quality in healthy males 20-45 years of age with no significant comorbidities who are able to produce a semen sample via masturbation. The main question it aims to answer is:

• Do shorter abstinence periods result in improved semen quality?

Participants will provide semen samples for analysis following abstinence periods of 7 days, 5 days, 2 days, 1 day, and 3 hours.

Detailed description: Participant Duration: Total length of time on study per subject is 14 days (including 5 days of visit required for sample production). Subjects do not need to complete the visits in order but need to document abstinence period prior to sample production. No follow up will be needed after the study.

Primary Objective: The primary objective is to examine the differences in semen analysis parameters after varying abstinence periods (7 days, 5 days, 2 days, 1 day, 3 hours).

Secondary Objectives: The secondary objective(s) is to assess changes in sperm DNA fragmentation after varying abstinence periods (7 days, 5 days, 2 days, 1 day, 3 hours).

Eligibility criteria: Inclusion Criteria:

* Males, aged 20-45 years
* Healthy, no significant comorbidities
* Able to produce a semen sample by masturbation
* Total sperm count ≥ 1 million sperm
* Abnormal sperm DNA fragmentation (TUNEL assay value ≥ 20%)

Exclusion Criteria:

* Age \< 20 or \> 45 years
* Significant comorbidities, including significant cardiac, pulmonary, gastrointestinal, hematologic, or neurologic disease
* Total sperm count \< 1 million sperm
* Aspermia (semen volume = 0)
* Normal sperm DNA fragmentation (TUNEL assay value \< 20%)

Primary outcomes:
measure: Change in semen analysis parameters based on different abstinence periods: volume
timeFrame: 7 days, 5 days, 2 days, 1 day, 3 hours
measure: Change in semen analysis parameters based on different abstinence periods: sperm concentration
timeFrame: 7 days, 5 days, 2 days, 1 day, 3 hours
measure: Change in semen analysis parameters based on different abstinence periods: motility
timeFrame: 7 days, 5 days, 2 days, 1 day, 3 hours
Secondary outcomes:
measure: Change in sperm DNA fragmentation based on different abstinence periods
timeFrame: 7 days, 5 days, 2 days, 1 day, 3 hours
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Cornell Medicine
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Jonathan Gal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03463863: Midurethral Sling With Autologus Rectus Sheath
Official title: The Safety And Efficacy Of Autologus Rectus Sheath Fascia As A Midurethral Transobturator Tension Free Vaginal Tape For Treatment Of Stress Urinary Incontinence.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Stress Urinary Incontinence
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2018-03-13
Enrollment: 70
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: assessment of the safety and efficacy surgeon tailored rectus sheath midurethral sling

Detailed description: the rectus sheath is harvested in 5 cm length and 2 cm width , A 2cm width 8 cm length polypropolyine mesh is attached to the harvest rectus sheet sling on both side The procedure is carried with a similar technique to the outside in TOT.

Eligibility criteria: Inclusion Criteria:

* stress incontinence

Exclusion Criteria:

* overactive bladder

Primary outcomes:
measure: cure rate of stress incontinence
timeFrame: one year after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr El Ainiy Hospital
Study officials:
References:
Clinical trial NCT05828563: Immunological Indices and Infections Among Pesticide Applicators in Sohag Governorate
Official title: Immunological Indices and Infections Among Pesticide Applicators in Sohag Governorate
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pesticide Adverse Reaction
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-04-25
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The human body gets exposure to pesticides either directly or indirectly. By using pesticides on crops, humans come in direct contact with them and they affect the heaith

Immune system is the first defense line against pathogenic organisms; however, it is altered by the vulnerable environmental factors such as pesticides, which can cause structural or functional alterations in humoral or cell mechanisms (nonspecific or adaptive) of the immune response which lead to an increase in the susceptibility to infections


Eligibility criteria: Inclusion Criteria:

1. pesticide applicators
2. Age ;20-60 years
3. Exposure to pesticides for more than 3 months

Exclusion Criteria:

* Subjects have recent severe trauma or surgery or recent infections

Primary outcomes:
measure: immunlogical indices
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University
Study officials:
References:
citation: Hadnagy W, Leng G, Sugiri D, Ranft U, Idel H. Pyrethroids used indoors--immune status of humans exposed to pyrethroids following a pest control operation--a one year follow-up study. Int J Hyg Environ Health. 2003 Mar;206(2):93-102. doi: 10.1078/1438-4639-00201.
citation: Kalyabina VP, Esimbekova EN, Kopylova KV, Kratasyuk VA. Pesticides: formulants, distribution pathways and effects on human health - a review. Toxicol Rep. 2021 Jun 6;8:1179-1192. doi: 10.1016/j.toxrep.2021.06.004. eCollection 2021.
citation: Zhang W, Lin Z, Pang S, Bhatt P, Chen S. Insights Into the Biodegradation of Lindane (gamma-Hexachlorocyclohexane) Using a Microbial System. Front Microbiol. 2020 Mar 27;11:522. doi: 10.3389/fmicb.2020.00522. eCollection 2020.
Clinical trial NCT03268863: Evaluating VR Therapy Using Cold Pressor Test
Official title: Using the Cold Pressor Test to Assess Effectiveness of Low-Cost, Immersive Virtual Reality Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Keywords: pain tolerance
perioperative pain
virtual reality therapy
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2017-08-31
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study is testing whether or not low-cost, virtual reality (VR) headsets for mobile phones can be used as a potential distractor from pain and thus would have clinical applications as a low-cost, non-pharmaceutical method to increase pain tolerance in patients undergoing painful or uncomfortable procedures. To do this, the investigators are asking volunteers to submerge their hand up to the wrist in cold water (Cold Pressor Test), either while playing an interactive virtual reality game on the headset, or while wearing a VR headset that is turned off as a control. The investigators will record the participants' tolerance to cold water as measured by how long the participants are able to keep their hand in the cold water.


Eligibility criteria: Inclusion Criteria:

* Healthy adult Mayo Clinic students and employees

Exclusion Criteria:

* Participants who are known to be sensitive to VR technology and/or have undesirable reactions to VR technology (i.e. dizziness, motion sickness)
* Participants with significant alcohol/smoking histories, sickle cell anemia, history of previous myocardial infarction and/or coronary artery disease, malignant hypertension, metabolic
* dysfunctions, pregnancy, Raynaud's disease, epilepsy, severe mental disorders, chronic pain conditions, or diseases producing neuropathic pain
* Participants that have used drugs/alcohol the day prior to the study

Primary outcomes:
measure: Pain Tolerance
timeFrame: 10 minutes
Secondary outcomes:
measure: Pain threshold
timeFrame: 10 minutes
measure: maximal pain
timeFrame: 10 minutes
measure: Nausea
timeFrame: 10 minutes
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Janet Vittone
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01318863: A Normal Donor Sample Collection Study in Healthy Adults
Official title: A Normal Donor Sample Collection Study in Healthy Adults
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Normal Volunteers
Keywords: aged matched normal control samples
Lead sponsor: Astute Medical, Inc.
Sponsor class: INDUSTRY
First posted: 2011-03-21
Enrollment: 300
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy Adults

Brief summary: More than one site will participate in the collection of blood and urine samples from healthy adult subjects. These samples will be used for future testing to serve as aged-matched normal controls and to establish normal reference ranges in the development of new invitro diagnostic devices.


Eligibility criteria: Inclusion Criteria:

* Apparently healthy adults (age ≥ 21 years)
* Provide written informed consent for study participation

Exclusion Criteria:

* Any known or suspected acute illness or condition - including acute infections - at the time of enrollment or within the previous 30 days;
* Any known or suspected significant chronic medical conditions (such as diabetes, coronary artery disease, renal insufficiency, hypertension, hypercholesterolemia, chronic inflammatory diseases \[e.g., rheumatoid arthritis\], cancer, etc);
* Trauma-related surgery within the last 6 months;
* Any surgery, hospitalization or institutionalization (such as in a nursing home) during the previous 3 months;
* Received any blood product transfusion within the previous 2 months;
* Pregnant women or children;
* Prisoners or institutionalized individuals;
* Already provided blood or urine samples for this study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Santa Ana
country: United States
facility: Apex Research Institute
state: California
city: Las Vegas
country: United States
facility: Clinical Research Consortium
state: Nevada
city: Rochester
country: United States
facility: Rochester Clinical Research, Inc.
state: New York
city: Gray
country: United States
state: Tennessee
city: Memphis
country: United States
state: Tennessee
city: Dallas
country: United States
facility: Research Across America
state: Texas
Study officials:
References:
Clinical trial NCT01790763: Compare the Efficacy of Mepilex and Keramatrix in Second Degree Burn Wounds
Official title: Prospective,Randomized, Parallel Study to Compare the Efficacy of Mepilex and Keramatrix in Promoting Healing of Second Degree Burn Wounds
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
PHASE3
Conditions: Skin Burn Degree Second
Keywords: Burn
Second-degree
Lead sponsor: The University of Texas Medical Branch, Galveston
Sponsor class: OTHER
Collaborators: name: Keraplast Technologies, LLC
name: Shriners Hospitals for Children
First posted: 2013-02-13
Enrollment: 0
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the extent to which Keramatrix dressing promotes the healing of second-degree burn wounds in pediatric patients.

Detailed description: Efficacy in promoting wound healing will be determined through comparison to Mepilex, an established burn wound dressing.

Eligibility criteria: Inclusion Criteria:

patient age 0-18 years old Flame or scald burn 10-30% total body surface area burned Partial-thickness second-degree burns Admission within 72 hours of burn injury Clean non-infected wound as diagnosed by the attending physician

Exclusion Criteria:

* Patient older than 18
* Causes other than flame or scald injuries (ie.chemical or frostbite)
* Wounds noted to be contaminated or infected
* Patients who have received previous treatment efforts (topical dressings or previous wound debridement)
* Pregnancy lactation
* Co-morbidity which may compromise healing: known history of AIDS, ARC, HIV, cancer, autoimmune diseases,cirrhosis, tuberculosis, chronic glucocorticoid therapy, diabetes mellitus, renal insufficiency, hepatic disease, congestive heart failure prior to burn injury, associated severe head injury requiring specific treatment
* known allergy to sheep's wool

Primary outcomes:
measure: Wound Healing
timeFrame: Duration of hospital stay, an expected average of 0.75 days per every percent burn until wound heals
Secondary outcomes:
measure: Infection rates
timeFrame: Duration of hospital stay, an expected average of 0.75 days per percent burn until wound heals
measure: Scarring
timeFrame: 52 weeks up to 78 weeks
measure: Pain
timeFrame: duration of hospital stay, an expected average of 0.75 days per every percent burn until wound heals, up to 3 times a week during dressing changes
Other outcomes:
Locations:
city: Galveston
country: United States
facility: Shriners Hospitals for Children
state: Texas
Study officials:
affiliation: University of Texas
name: Carlos Jimenez, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03679663: Ultrasound Versus Palpation for Spinal Anesthesia Success
Official title: Prospective Randomized Controlled Trial to Compare a Handheld Ultrasound Identification of the Neuraxial Block Insertion Site Versus Palpation Only in an Obese Population of Women Undergoing Cesarean Delivery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ultrasound
Keywords: ultrasound
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2018-09-20
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: RCT
Primary purpose: DIAGNOSTIC

Brief summary: Aim is to investigate the difference in number of attempts to place neuraxial block comparing handheld ultrasound versus use of palpation alone for women with impalpable bony landmarks undergoing spinal anesthesia for elective cesarean delivery.

Detailed description: Patients will be recruited prior to cesarean delivery and their site of lumbar injection will be examined. Women with impalpable bony landmarks will be offered recruitment to the study. Women will be randomly assigned to the standard of care group - palpation attempts only, versus an ultrasound group, where the insertion point will be identified by the handheld ultrasound device

Inclusion criteria:

Lumbar spinous processes impalpable. Elective cesarean delivery for singleton pregnancies BMI \>30 No contraindications to neuraxial block Signed informed consent Neuraxial Block planned Exclusion Criteria Refuses informed consent Poor written Hebrew, no spoken English or Hebrew Patients will be randomized into two groups : an ultrasound (US) group and a palpation (PP) group.

The primary outcome of our study is the number of needle redirections, defined as any ventral advancement of the needle and/or introducer, as well as any new intervertebral space attempted.

Secondary outcomes include:

The insertion site identification time, patient verbal numerical pain score (0-10) after skin incision.

Eligibility criteria: Inclusion Criteria:

Lumbar spinous processes impalpable. Elective caesarean delivery for singleton pregnancies BMI \>30 No contraindications to neuraxial block Signed informed consent Neuraxial Block planned

Primary outcomes:
measure: Needle movement
timeFrame: 10 mins
Secondary outcomes:
measure: The insertion site identification time,
timeFrame: 10 mins
measure: Patient verbal numerical pain score (0-10) after skin incision.
timeFrame: 10 mins
measure: Patient verbal numerical pain score (0-10) after spinal performance. Patient verbal numerical pain score (0-10). Scale is Verbal numerical rating scale, where zero = no pain at all and 10 = maximum possible pain.
timeFrame: 10 mins
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center
Study officials:
References:
Clinical trial NCT03939663: Role of Vaginal Misoprostol Prior to IUCD Insertion in Women Who Delivered Only by Elective Caesarean Section.
Official title: Role of Vaginal Misoprostol Prior to IUCD Insertion in Women Who Delivered Only by Elective Caesarean Section.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: IUD Insertion Complication
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2019-05-07
Enrollment: 210
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Role of vaginal misoprostol prior to IUCD insertion in women who delivered only by elective caesarean section.

Detailed description: Misoprostol ( 400mcg ) vaginally administrated 3 hours prior to IUCD insertion increases the ease and success of insertion and decrease associated pain among women who had delivered only by elective caesarean section.

Eligibility criteria: Inclusion Criteria:

* All women will be 20 to 40 years of age.
* Desires IUCD placement and able to participate.
* Negative pregnancy test.
* Willing to follow- up in 6-8 weeks for a standard IUCD follow-up visit.
* Delivered only by cesarean section.

Exclusion Criteria:

* Active cervical infection.
* Current pregnancy.
* Uterine anomaly.
* Fibroid uterus.
* Copper allergy/Wilson's disease.
* Undiagnosed abnormal uterine bleeding.
* Cervical or uterine cancer.
* Allergy to misoprostol.
* Previous vaginal delivery.

Primary outcomes:
measure: the proportion of failed IUCD insertions regardless of the reason .
timeFrame: during insertion
measure: the degree of difficulty of the IUCD insertion .
timeFrame: during insertion
Secondary outcomes:
measure: heavy bleeding
timeFrame: 7 days
measure: partial or total expulsion
timeFrame: 4 to 6 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Enas Mahmoud
Study officials:
References: